Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Subscribe To Our Newsletter & Stay Updated